Market Segmentation:
- By Product Type
- Amikacin
- Gentamicin
- Tobramycin
- Neomycin
- Streptomycin
- Paromomycin
- Others (Kanamycin, Netilmicin, Plazomicin)
- By Route of Administration
- Intravenous
- Intramuscular
- Topical
- Inhalation
- Others (Oral, Ophthalmic)
- By Application
- Respiratory Tract Infections
- Urinary Tract Infections
- Septicemia
- Endocarditis
- Meningitis
- Bone and Joint Infections
- Others (Peritonitis, Abdominal Infections)
- By End-user
- Hospitals
- Clinics
- Ambulatory Surgical Centers
- Home Care Settings
- Others (Long-term Care Facilities, Veterinary Settings)
- By Regions
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East & Africa
Frequently Asked Questions
The current market size of the Aminoglycoside Antibiotics industry is US$ 1.2 billion.
The key factors hampering the growth of the Aminoglycoside Antibiotics Market are: side effects concerns, stringent regulatory requirements, competition from alternative therapies, high development costs, limited pipeline, resistance development, dosing complexities, nephrotoxicity, ototoxicity, and supply chain disruptions.
The key factors driving the growth of the Aminoglycoside Antibiotics Market are: rising prevalence of bacterial infections, increasing antibiotic resistance, growing healthcare expenditure, aging population, advancements in diagnostic techniques, novel antibiotic development, and implementation of antibiotic stewardship programs.
The leading component segment in the Aminoglycoside Antibiotics Market is the amikacin segment, widely used for treating resistant bacterial infections.
The major players operating in the Aminoglycoside Antibiotics Market are Pfizer Inc., Novartis AG, Sanofi, Merck & Co., Inc., GlaxoSmithKline plc, Bayer AG, Eli Lilly and Company, Bristol-Myers Squibb Company, AbbVie Inc., Astellas Pharma Inc., Achaogen, Inc., Melinta Therapeutics, Inc., Allergan plc, Teva Pharmaceutical Industries Ltd., Wockhardt Ltd., Xellia Pharmaceuticals ApS, Cipla Ltd., Lupin Ltd., Zydus Cadila, and Aurobindo Pharma Ltd.
The North America region is expected to lead the Aminoglycoside Antibiotics Market, with a market share of 35.2% in 2023.
The key drivers of the Aminoglycoside Antibiotics Market are rising prevalence of bacterial infections, increasing antibiotic resistance, growing healthcare expenditure, aging population, advancements in diagnostic techniques, novel antibiotic development, and implementation of antibiotic stewardship programs.